Compare ZCMD & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZCMD | CDT |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | China | United States |
| Employees | N/A | 4 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 2.4M |
| IPO Year | 2019 | N/A |
| Metric | ZCMD | CDT |
|---|---|---|
| Price | $1.10 | $3.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.7M | 133.2K |
| Earning Date | 04-28-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.30 |
| 52 Week High | $11.96 | $11.00 |
| Indicator | ZCMD | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 64.00 |
| Support Level | $0.75 | $2.57 |
| Resistance Level | $2.70 | $3.90 |
| Average True Range (ATR) | 1.14 | 0.42 |
| MACD | -0.10 | 0.06 |
| Stochastic Oscillator | 0.73 | 51.09 |
ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.